Teresa Gorria
Barcelona, CT 08028, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Lung Cancer Screening and Prevention: Beyond Conventional Strategies in a Rapidly Changing Global Milieu.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 21, 2026
Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 29, 2026
Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer.
Journal: The Lancet. Oncology
Published: February 28, 2026
Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.
Journal: Clinical pharmacokinetics
Published: February 25, 2026
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.
Journal: Science translational medicine
Published: February 04, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 23, 2025
Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort.
Journal: Cancer medicine
Published: September 08, 2025
Radon risk mapping in Spain: a population and building-inclusive approach.
Journal: Environment international
Published: August 28, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50.
Journal: ESMO open
Published: August 26, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 17, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Journal: Journal for immunotherapy of cancer
Published: July 31, 2025
Last Updated: 09/26/2026